A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice

Clinical Cancer Research

Volumn 15, Issue 23, 2009, Pages 7256-7265

  Malvicini, Mariana ^a   Rizzo, Miguel ^a   Alaniz, Laura ^a,c   Piñero, Federico ^a   García, Mariana ^a,c   Atorrasagasti, Catalina ^a   Aquino, Jorge B ^a,c   Rozados, Viviana ^b   Scharovsky, O Graciela ^b   Matar, Pablo ^b,c   Mazzolini, Guillermo ^a,c  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; TRANSCRIPTION FACTOR FOXP2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOSE RESPONSE; DRUG POTENCY; DRUG POTENTIATION; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPOTENTIATION; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; SURVIVAL TIME; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA; CD4-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; CYCLOPHOSPHAMIDE; FORKHEAD TRANSCRIPTION FACTORS; GENE THERAPY; GENE TRANSFER TECHNIQUES; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MICE; MICE, INBRED BALB C;

EID: 73149125743     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1861     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4.
3. Croci DO, Zacarías Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 2007;56:1687-700.
4. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-22.
5. Kirkwood J. Cancer immunotherapy: the interferon-α experience. Semin Oncol 2002;29:18-26.
6. Colombo M, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994;15:48-51.
7. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:155-68.
8. Mazzolini G, Narvaiza I, Bustos M, et al. α(v)β(3) integrin-mediated adenoviral transfer of interleukin-12 at the periphery of hepatic colon cancer metastases induces VCAM-1 expression and T cell recruitment. Mol Ther 2001;3:665-72.
9. Ogawa M, Umehara K, Yu WG, et al. A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression. Cancer Res 1999;59:1531-8.
10. Angiolillo AL, Sgadari C, Taub DD, et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182:155-62.
11. Narvaiza I, Mazzolini G, Barajas M, et al. Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-γ-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy. J Immunol 2000;164:3112-22.
12. Mazzolini G, Prieto J, Melero I. Gene therapy of cancer with interleukin-12. Curr Pharm Des 2003;9:1981-91.
13. Mazzolini G, Qian C, Xie X, et al. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther 1999;6:514-22.
14. Adris S, Chuluyan E, Bravo A, et al. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells. Cancer Res 2000;60:6696-703.
15. Barajas M, Mazzolini G, Genove G, et al. Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin12. Hepatology 2001;33:52-61.
16. Caruso M, Pham-Nguyen K, Kwong YL, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A 1996;93:11302-6.
17. Putzer BM, Stiewe T, Rodicker F, et al. Large nontransplanted hepatocellular carcinoma in woodchucks: treatment with adenovirus-mediated delivery of interleukin 12/B7.1 genes. J Natl Cancer Inst 2001;93:472-9.
18. Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004;22:1389-97.
19. Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 2007;220:82-101.
20. Melero I, Mazzolini G, Narvaiza I, Qian C, Chen L, Prieto J. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol 2001;22:113-5.
21. Teicher BA. Antitumor alkylating agents. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer-Principles and Practice of Oncology. Philadelphia: Lippincott-Raven; 1997, p. 405-18.
22. Matar P, Celoria GC, Font MT, Scharovsky OG. Antimetastatic effect of a single-low dose of cyclophosphamide on a rat lymphoma. J Exp Clin Cancer Res 1995;14:59-63.
23. Matar P, Rozados VR, González AD, Dlugovitzky DA, Bonfil RD, Scharovsky OG. Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. Eur J Cancer 2000;36:1060-6.
24. Matar P, Rozados VR, Roggero EA, Bonfil RD, Scharovsky OG. Modulation of the antimetastatic effect of a single low dose of cyclophosphamide on rat lymphoma. Tumor Biol 1998;19:69-76.
25. Gold JE, Zachary DT, Osband ME. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma. Int. J. Cancer 1995;61:580-6.
26. Matar P, Rozados VR, Gervasoni SI, Scharovsky OG. Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int Immunopharmacol 2001;1:307-19.
27. Matar P, Rozados VR, Gervasoni SI, Scharovsky OG. Th2/Th1 switch induced by a single low-dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 2002;50:588-96.
28. Qian C, Bilbao R, Bruña O, Prieto J. Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology 1995;22:118-23.
29. Reed LJ, Muench H. A simple method of estimating fifty per cent points. Am J Hyg 1938;27:493-7.
30. Wunderlich J, Shearer G, Livingstone A. Induction and measurement of cytotoxic T lymphocyte activity. Curr Protoc Immunol 1997;21:3.11.1-3.11.20.
31. Brode S, Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 2008;28:109-26.
32. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000;60:2190-6.
33. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Cutting wdge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004;172:4676-80.
34. Matar P, Alaniz L, Rozados V, et al. Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci 2009;6:30.
35. Qian C, Liu XY, Prieto J. Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res 2006;16:182-8.
36. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008;20:241-6.
37. Lutsiak MEC, Semnani RT, De Pascalis R, Kashmiri SVS, Schlom J, Sabzevari H. Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8.
38. Taieb J, Chaput N, Schartz N, et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 2006;176:2722-9.
39. Awwad M, North RJ. Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Cancer Res 1988;49:1649-54.
40. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
41. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005;174:4465-9.
42. Proietti E, Greco G, Garrone B, et al. Importance of cyclophosphamide- induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 1998;101:429-41.
43. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004;34:336-44.
44. HungK,HayashiR, Lafond-Walker A,Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
45. Lanzavecchia A. Immunology. Licence to kill. Nature 1998;393:413-4.
46. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998;4:581-7.